Crown Bioscience, Inc. Strengthen Position In Europe With Appointment Of New Business Development Manager

Santa Clara, CA (12th March 2015) – Crown Bioscience, Inc., a leading global drug discovery and development service company welcomes Sebastian Dempe as Business Development Manager for central Europe. Following the acquisition of Molecular Response and the appointment of a new Senior Vice President Global Strategy earlier this year, this announcement is a crucial development in Crown's global expansion strategy and promises to considerably strengthen the company's position within the European drug discovery market.

Dempe has over eight years of experience working within the oncology research community, with extensive knowledge of in vitro and in vivo studies of human pancreatic adenocarcinomas, as well as virotherapy of cancer using natural and armed oncolytic parvoviruses, strengthening anticancer immune responses. With more than three years as Business Development Manager for ProQinase, Dempe specialises in promoting recombinant kinases as well as R&D services, and has developed a substantial network of industry contacts within Germany and wider Europe. As Crown's BD manager based in Germany, he will continue to engage with drug developers primarily based in Germany, Switzerland and Austria, as part of Crown's growing European network of BD managers providing local support for European clients across Europe.

"Sebastian is a welcome addition to the team, bringing with him a wealth of experience working within a key geography for drug discovery" comments Laurie Heilmann, recently appointed Senior Vice President Global Strategy of Crown Bioscience Inc. "As part of our ambitious growth strategy, his considerable knowledge of the industry, coupled with his influence in the local drug discovery community, will provide us with a considerable advantage in strengthening our existing operations and leveraging our position within the European market."

The appointment of Mr Dempe, follows several high profile announcements made in the first quarter of 2015. With the recent acquisition of Molecular Response, Crown has the largest and most comprehensive collection of clinically and ethnically diverse patient derived xenograft (PDX) models in the world. In February, Crown also announced the expansion of its partnership with the National Resource Center for Mutant Mice to develop novel immuno-oncology mouse models for use in immunotherapy research. With new appointments in key geographies Crown is now moving to establish global access to its superior service platforms and reinforce its commitment to assisting drug development companies reduce cancer to a manageable chronic disease.

For further information about Crown Bioscience visit the website at:

~ ENDS ~

For further press information please contact: Celine Goodier - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: [email protected]

About Crown Bioscience Inc.

Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Since acquiring new assets and facilities in San Diego, our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms now contain the largest and most clinically and ethnically diverse collection of patient-relevant models in the world, enabling unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Crown Bioscience UK Ltd. In Nottingham) and the USA (Kannapolis NC, San Diego CA) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, please visit

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.